BAC will use its CaptureSelect technology to make custom affinity ligands.
BAC inked a collaboration with Bristol-Myers Squibb (BMS) to generate affinity ligands for the purification and analysis of BMS’ Adnectins™ biologics. BAC will work to discover and develop custom ligands on its CaptureSelect platform.
“Our CaptureSelect platform enables us to produce ligands that have high affinity and specificity for individual proteins and facilitates the generation of an exceptionally pure product in a single purification step,” comments Laurens Sierkstra, CEO of BAC. “We are delighted to collaborate with Bristol-Myers Squibb on the development of ligands for their Adnectin proteins. These custom ligands should simplify the purification process.”
Derived from human fibronectin, Adnectins are engineered using BMS’ PROfusion™ technology to either block or stimulate the action of specific targets across a range of therapeutic areas. BMS acquired these compounds when it bought Adnexus Therapeutics in October 2007.